Day One Biopharmaceuticals reported Q4 net product revenue from OJEMDA of USD 52.8 million and FY 2025 net product revenue of USD 155.4 million, with the FY figure up 172% year over year. Q4 license revenue was USD 0.9 million and FY license revenue was USD 2.8 million. Day One Biopharmaceuticals posted a Q4 net loss of USD 21.3 million and a FY net loss of USD 107.3 million, and ended 2025 with USD 441.1 million in cash, cash equivalents and short-term investments. For OJEMDA, Q4 prescription volumes were 1,394 and total 2025 prescriptions were 4,635, up 181% versus 2024. Day One Biopharmaceuticals reaffirmed 2026 U.S. OJEMDA net product revenue guidance of USD 225 million to USD 250 million. On the pipeline, the company highlighted updated three-year data from the Phase 2 FIREFLY-1 trial presented in November 2025 and said the Phase 3 FIREFLY-2 frontline pLGG trial remains on track with full enrollment expected in H1 2026. The company also noted its January 2026 acquisition of Mersana Therapeutics, with updated Phase 1 data for Emi-Le expected mid-2026, and said its Phase 1a DAY301 program is progressing, with initial clinical data and an update planned for H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602241600PRIMZONEFULLFEED9660363) on February 24, 2026, and is solely responsible for the information contained therein.